Axonics, Inc. (NASDAQ:AXNX - Get Free Report) CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total value of $205,523.01. Following the sale, the chief financial officer now directly owns 40,362 shares in the company, valued at $2,801,526.42. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Axonics Stock Up 0.2 %
NASDAQ:AXNX opened at $69.63 on Friday. The firm has a market capitalization of $3.55 billion, a PE ratio of -217.59 and a beta of 0.81. Axonics, Inc. has a twelve month low of $48.30 and a twelve month high of $69.91. The stock's 50-day simple moving average is $68.93 and its 200 day simple moving average is $68.05.
Axonics (NASDAQ:AXNX - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.10 by $0.03. The firm had revenue of $114.57 million during the quarter, compared to the consensus estimate of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The business's quarterly revenue was up 23.3% on a year-over-year basis. During the same period last year, the company earned ($0.15) earnings per share. On average, analysts anticipate that Axonics, Inc. will post 0.24 EPS for the current fiscal year.
Analysts Set New Price Targets
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a report on Monday, August 5th. Eight investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $69.57.
Read Our Latest Analysis on Axonics
Hedge Funds Weigh In On Axonics
Hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC raised its position in shares of Axonics by 31.1% during the first quarter. Headlands Technologies LLC now owns 1,117 shares of the company's stock worth $77,000 after acquiring an additional 265 shares during the last quarter. Whittier Trust Co. increased its holdings in Axonics by 59.1% in the first quarter. Whittier Trust Co. now owns 1,142 shares of the company's stock worth $79,000 after purchasing an additional 424 shares in the last quarter. Inspirion Wealth Advisors LLC bought a new stake in Axonics in the first quarter worth approximately $207,000. Xponance Inc. increased its holdings in Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company's stock worth $217,000 after purchasing an additional 225 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in Axonics in the first quarter worth approximately $218,000. 99.48% of the stock is currently owned by institutional investors.
About Axonics
(
Get Free Report)
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
